- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00687440
A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)
Pegylated Liposomal Doxorubicin (Caelyx) in Combination With Herceptin and Taxotere as First-line Chemotherapy in Metastatic Breast Cancer Patients: A 2 Stage Phase II, Open Label, Multicenter Study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must fulfill all the following criteria:
- Females aged 18 to 70 years-old.
- Willingness to participate in the study and comply with its procedures.
- Documented diagnosis of metastatic breast carcinoma (stage IV) Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing (Immunohistochemistry (IHC) 3+ or Fluorescence In Situ Hybridization(FISH) +).
- No prior chemotherapy for metastatic breast cancer.
Adjuvant or neo-adjuvant chemotherapy is allowed according to the following rules:
patients treated with anthracyclines if all the following conditions are met:
- Doxorubicin total dose <= 300 mg/m^2
- Epirubicin total dose <= 480 mg/m^2
- Chemotherapy-free interval of > 12 months
- no taxane-based adjuvant or neo-adjuvant chemotherapy is allowed;
- patients treated with non-anthracycline/taxane adjuvant or neo-adjuvant chemotherapy regimens are freely eligible (i.e. cyclophosphamide/methotrexate/fluorouracil (CMF) or similar regimens).
- At least one measurable lesion according to RECIST criteria.
- Complete hematologic and biologic baseline evaluation within 2 weeks prior to start of treatment.
- Complete Tumor baseline evaluation including a total body computed tomography (CT) scan within 4 weeks prior to start of treatment.
- Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram or Multi Gated Acquisition (MUGA) scan.
- World Health Organization (WHO) performance status 0,1.
- Life expectancy > 3 months.
Laboratory requirements :
Hematology :
- Neutrophils > 1.5 x 10^9/L
- Platelets > 100 x 10^9/L
- Hemoglobin > 10 g/dL
Hepatic function:
- Total bilirubin <= 1.25 x the upper-normal limits (UNL);
- ASAT (Aspartate Aminotransferase or SGOT), ALAT (Alanine aminotransferase or SGPT) <= 2.5 x the upper-normal limits;
For patients with liver metastases:
- Total bilirubin < 1.5 x the UNL (Upper limit of normal) ;
- ASAT and/or ALAT < 3 x the UNL;
Renal function :
- Serum Creatinine < 1.5 x the UNL.
- Women of child bearing potential must have a negative serum pregnancy test and be using adequate contraception.
- Patients must be accessible for treatment and follow-up.
Exclusion Criteria:
Patients will not be enrolled if any of the following criteria apply:
- Prior chemotherapy for metastatic disease.
- History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ).
- Radiation to disease areas within 3 weeks of study initiation.
- Symptomatic peripheral neuropathy > grade 2 according to the National Cancer Institute (NCI) Common Toxicity Criteria.
- Other serious illness or medical condition.
- LVEF < 50% as determined by echocardiogram or MUGA scan.
- Congestive hearth failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia.
- History of significant neurologic or psychiatric disorders including dementia or seizures.
- Active infection.
- Active peptic ulcer, unstable diabetes mellitus or other contraindications for the use of dexamethasone.
- Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening.
- Concurrent treatment with corticosteroids used for reasons other than for premedication. However patients receiving chronic treatment with corticosteroids (> 6 months) at low dose (< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible.
- Taxane-based adjuvant or neo-adjuvant chemotherapy < 12 months.
- Other concurrent chemotherapy, immunotherapy, radiotherapy or any other investigational medication, for the treatment of the tumor.
- Pregnant or breast-feeding women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Caelyx, Docetaxel, Trastuzumab
Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of cardiac events, subjects will proceed to a second stage or restart with a lower dose of Caelyx. Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab. |
Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m^2 on day 1, every 3 weeks Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks.
Other Names:
Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
Other Names:
Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose.
Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Had a Tumor Response, According to Standard RECIST (Response Evaluation Criteria in Solid Tumors) Criteria
Time Frame: Week 09, Week 18, at the end of each patient's treatment, and at 3, 6, 9, and 12 months after end of treatment.
|
Those who achieved either complete (disappearance of all target lesions) or partial (at least 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD) response.
|
Week 09, Week 18, at the end of each patient's treatment, and at 3, 6, 9, and 12 months after end of treatment.
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Antibiotics, Antineoplastic
- Docetaxel
- Trastuzumab
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- P03679
- Eudract No. 2004-003989-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasm
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Not yet recruitingBreast Cancer | Neoplasm, Breast | Malignant Neoplasm of Breast | Breast Tumor | Mammary Cancer | Mammary Neoplasms, Human | Tumor, Breast | Mammary NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Triple-Negative Breast CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterU.S. Army Medical Research and Development Command; U.S. Army Medical Research...CompletedBreast Carcinoma | Malignant Breast Neoplasm | Benign Breast NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast CarcinomaUnited States
-
Indiana UniversityIndiana University HealthCompletedBreast Cancer | Breast Neoplasms | Anxiety | Breast Carcinoma | Fear | Cancer of Breast | Malignant Tumor of Breast | Malignant Neoplasm of Breast | Mammary Cancer | Human Mammary Carcinoma | Mammary Neoplasm, Human | Mammary Carcinoma | Neoplasm Remission, Spontaneous | Spontaneous Neoplasm Regression | Regression,... and other conditionsUnited States
-
National Cancer Institute, ThailandCompleted
-
Umbria Bioengineering TechnologiesToscana Life Sciences Sviluppo s.r.l.; London South Bank University; ELAROS 24... and other collaboratorsRecruitingWomen's Health: Neoplasm of BreastItaly, Spain, Poland, Portugal, Switzerland
-
Istanbul Aydın UniversityActive, not recruiting
-
University of OviedoCompletedWomen's Health: Neoplasm of BreastSpain
-
National Cancer Institute, ThailandCompleted
Clinical Trials on Pegylated Liposomal Doxorubicin
-
Sun Yat-sen UniversityUnknown
-
GlaxoSmithKlineCompletedNeoplasms, OvarianUnited States
-
MedSIRRoche Pharma AG; ExperiorCompleted
-
National Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC...United States
-
National Cancer Institute (NCI)CompletedDS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Fudan UniversityRecruiting
-
Cancer Institute and Hospital, Chinese Academy...CSPC Ouyi Pharmaceutical Co., Ltd.UnknownHER2-positive Breast CancerChina
-
ARCAGY/ GINECO GROUPCompleted
-
European Organisation for Research and Treatment...CompletedBreast CancerFrance, Spain, Netherlands, United Kingdom, Italy, Israel, Switzerland, Greece, Austria
-
University of ArizonaTerminatedBreast CancerUnited States